Core outcome set for preventive intervention trials in chronic and episodic migraine (COSMIG): an international, consensus-derived and multistakeholder initiative

Kirstie Haywood, Rachel Potter, Robert Froud, Gemma Pearce, Barbara Box, Lynne Muldoon, Richard Lipton, Stavros Petrou, Regina Rendas-Baum, Anne-Marie Logan, Kimberly Stewart, Martin Underwood, Manjit Matharu, on behalf of the CHESS COSMIG group

ABSTRACT

Objective Typically, migraine prevention trials focus on reducing migraine days. This narrow focus may not capture all that is important to people with migraine. Inconsistency in outcome selection across trials limits the potential for data pooling and evidence synthesis. In response, we describe the development of core outcome set for migraine (COSMIG).

Design A two-stage approach sought to achieve international, multistakeholder consensus on both the core domain set and core measurement set. Following construction of a comprehensive list of outcomes, expert panellists (patients, healthcare professionals and researchers) completed a three-round electronic-Delphi study to support a reduction and prioritisation of core domains and outcomes. Participants in a consensus meeting finalised the core domains and methods of assessment. All stages were overseen by an international core team, including patient research partners.

Results There was a good representation of patients (episodic migraine (n=34) and chronic migraine (n=42)) and healthcare professionals (n=33) with high response and retention rates. The initial list of domains and outcomes was reduced from >50 to 7 core domains for migraine. Participants in a consensus meeting finalised the core domains and methods of assessment. All stages were overseen by an international core team, including patient research partners.

Conclusion International and multistakeholder consensus emerged to describe a two-domain core outcome set for reporting research on preventive interventions for chronic and episodic migraine: migraine-specific pain and migraine-specific quality of life. Intensity of migraine pain assessed with an 11-point Numerical Rating Scale and the frequency as the number of headache/migraine days over a specified time period. Migraine-specific quality of life assessed using the Migraine Functional Impact Questionnaire.

BACKGROUND

International guidelines for the conduct of preventive studies for both episodic migraine (EM) and chronic migraine (CM) specify that the primary outcome should be focused on migraine days, or for CM on moderate to severe headache days. Reviews of clinical trials of populations with CM and EM have identified substantial inconsistencies in outcomes reporting alongside often poorly defined outcomes. An important impact of these inconsistencies is to limit the potential for robust meta-analyses. For example, a 2015 meta-analysis of drugs for the prophylaxis of migraine by Jackson et al did not include data from the largest and most robust trial of topiramate for CM (n=307) that found a mean difference of 1.7 migraine/migrainous days per 28 days after 12 weeks. The reviewers meta-analysed the data from two much smaller (n=32 and n=50), low quality studies, and reported an effect size of 8.4 headache days.

Strengths and limitations of this study

- The research process and validity of results are strengthened by the co-operation with patient research partners throughout all stages of the research.
- A bespoke grading system to support the prioritisation of outcome domains between stakeholder groups (expert panels) is described.
- International, multistakeholder participation of patients, researchers, and a range of health professionals in the on-line Delphi survey.
- Expert panel representation in the Delphi survey was largely from Europe and North America.
- The majority of participants in the face-to-face consensus meeting were from the UK.
Stage 2: recommending the core measurement set

Stage 1: defining the core domain set (CDS): what based COS applicable to preventative interest stakeholder.

Two key stages in COS development are described as methods.

Current international guidelines for conduct of prevention studies in EM or CM have not developed outcome reporting recommendations in line with the current best practice. Notably, patient input is markedly absent from these guidelines.

We describe here the development of a multi-stakeholder, internationally endorsed, consensus-based COS applicable to preventative intervention trials and research studies in adults with episodic or chronic MIGraine (COSMIG).

METHODS

Two key stages in COS development are described as follows (figure 1): Stage 1: defining the core domain set (CDS): what to measure, that is, the minimum number of health domains that should be assessed. A domain describes the concept or ‘aspect of health or a health condition that needs to be measured to appropriately assess the effects of a health intervention’. Stage 2: recommending the core measurement set (CMS): how to measure, that is, the minimum set of assessment methods that adequately correspond to the CDS.

We prospectively registered COSMIG with the Core Outcomes Measures in Effectiveness Trials initiative (http://www.comet-initiative.org/studies/details/953).

Patient and public involvement

Following good practice guidance, we worked collaboratively with our patient research partners, who all had experience of CM or EM, throughout all stages of the research. The COSMIG core group consisted of clinicians with expertise in headaches and migraine (MM, MU and Brendan Davies), including two international members (RL and Rigor Jensen), research scientists with expertise in clinical trials, Delphi technique, health measurement and qualitative research (MU, KH, RF, RP, SP, Vivien Nichols, Shilpa Patel and KS) and patient research partners (GP, BB and LM). Regular meetings were held between all group members to discuss the methodology for the Delphi study and the subsequent consensus meeting. The group met specifically between each Delphi round, to discuss results, confirm feedback and format for subsequent rounds.

Stage 1: core domain set

Stage 1.1: developing a comprehensive domain list

We first identified potential domains from systematic reviews and qualitative research. Domains were written in plain English as online questionnaires: one questionnaire contained domains for episodic headache, and one for chronic headache. Questionnaires were piloted with the core team and researchers naïve to the study (n=12).

Stage 1.2: international modified-Delphi process

Our primary goal for our Delphi study was to refine and prioritise domains. The Delphi process seeks to establish consensus between a panel of experts following a structured process of questionnaire completion and systematic feedback. The panels are not intended to be representative of all headache specialists or people with migraine (as is the case when sampling from a definable population). We defined two expert panels external to the core research team: one comprised of expert patients with a target of up to 50 with CM and 50 with EM; and a second panel (also up to 50) comprised of healthcare professionals and researchers, who were representative of their professions and well placed to implement study findings. Professionals included neurologists, nurse specialists, general practitioners, allied health professionals, researchers and measurement experts. We sought consensus between experts on the CDS.

Patients

We asked 13 national/international organisations to advertise the study on their social media platforms. Interested participants (≥18 years old) contacted the research team. We asked participants to self-diagnose/classify their migraines as EM or CM. Patient participants completed EM or CM questionnaires depending on their self-diagnosis.

Professionals

We invited national and international healthcare professionals (neurologists, General Practitioners (GPs), nurses, psychologists, pharmacists and allied health professionals) and researchers (trialists, reviewers, health economists and measurement experts) involved in headache research, identified through professional societies and from published research to participate. They were asked to complete both questionnaires.

The Delphi process had three sequential rounds with participants completing each prior round eligible to complete the next. The Delphi study administration and hosting of the online questionnaires was managed by Clinvivo.
Round 1: participants rated the relative importance of each domain for inclusion in future research studies of chronic or episodic headache using a 9-point Numerical Rating Scale (NRS) (range: 1–3 ‘Not at all important’, 4–6 ‘Uncertain’ and 7–9 ‘Very important’). Participants could elaborate on their decisions by providing additional qualitative comment and/or provide additional domains for consideration.
and rating in subsequent rounds. Informed by an approach described by Orbai et al., we devised a bespoke grading system to illustrate where consensus was achieved and to indicate more easily where participants in each panel disagreed in their judgement (online supplemental table 1). An a priori decision rule determined that only those outcome domains judged most favourably by one or both panels (patients and professionals) would be included in round 2. That is, domains were included in round 2 if in both panels the median rating was ≥7 (‘A*’), or if in both panels ≥70% rated a domain ≥7 (‘A’). If in both panels the median domain rating was ≥7 (‘A’), or the median rating for a domain was ≥7 in just one panel (‘B’), the domain could be included in round 2 if either panel achieved a median score of 9 or qualitative evidence supported further consideration.

Round 2: in round 2, we focused more specifically on migraine-specific domains (e.g., nausea and photosensitivity), rather than headache-specific domains. Responses to round 1 were summarised and anonymous feedback provided. All participants received their own score for each domain, and the group median scores. Further prioritisation was achieved by inviting participants to ‘spend points’ (up to a maximum of 70) to illustrate how strongly they felt that a domain should be prioritised for inclusion in the CDS; a maximum of 10 points could be allocated to any 1 outcome domain (11-point scale: from 0 ‘Not a priority’ to 10 ‘Absolute priority’). To ensure that subpanel differences were considered, and any discrepancies highlighted, the results from both panels were considered both separately and combined: the top 10 and top 50% of prioritised domains were discussed between COSMIG core team members, informing the maintenance of, or, where the concepts of health were similar, grouping of domains into a single ‘meaningful’ domain.

Round 3: responses to round 2 were summarised, highlighting the top 50% of prioritised domains and between-panel discrepancies. For those domains prioritised highly by just one panel (top 50%), participants were asked to reconsider if they should be included in the priority listing. If more than 70% of respondents selected ‘yes’, the domain was included. Finally, participants were asked to indicate by means of a dichotomous response if they: (a) were happy with the grouping of prioritised domains; (b) were happy with the proposed ‘meaningful’ domain and definition and (c) had additional comments. The frequency distribution of responses was calculated. Results from both subpanels were again considered separately and combined.

**Stage 2: core measurement set**

**International expert panel face-to-face meeting**

The purpose of the 1-day meeting was to discuss the CDS developed in our modified Delphi study, agree with the CMS and recommend the COS. Importantly, participants were to consider that while a domain may be considered important, if an acceptable approach to measurement is not available, it is not appropriate to include the domain in a COS.

We invited professionals from Europe and patients from the UK who had taken part in our Delphi study. Participants received an information pack with meeting objectives and domain/measurement information ahead of the meeting. Where existing consensus for potential measures was not available, the COSMIG core team reviewed key data sources for guidance and evidence of measurement quality, acceptability and feasibility for use in preventive studies of EM or CM:

- **Migraine/headache:**
  - Review of patient-reported outcome measures.
  - International Headache Society guidelines.
  - National Institute for Neurological Disorders Common Data Elements—Headache (preventative treatment).
- **Chronic pain and COS development:**
  - Initiative on Methods, Measurement and Pain Assessment in Clinical Trials.
  - Outcome Measures in Rheumatology and Clinical Trials group.

The meeting started with an overview of the results of the Delphi process, prioritised domains and the evidence-based underpinning potential methods of assessment. Participants were asked to consider three options when determining domain ‘placement’ within the final COS:

- Core ‘inner’ circle: domain is unambiguous with an acceptable method of assessment.
- Middle circle: domain is important, but not feasible for all preventative trials and research studies.
- Outer circle: domain is important but requires further study (research agenda)—for example, lacks conceptual clarity or method of assessment.

Semi-structured, small-group discussions with a mix of patients, healthcare professionals/researchers and members of the core research team (including patient partners) ensued, covering each prioritised domain. Two facilitators each supported two rounds of discussion per domain. Outcome domains and methods of assessment were reviewed in terms of importance, quality, acceptability and feasibility. Facilitators supported participant contribution and shared findings between groups to stimulate discussion. Following each small-group discussion, participants, with the exception of the core research team, were asked to indicate anonymously (paper-based questionnaire) their preference for domain inclusion (yes/no/do not know) and method of assessment (selecting one option from a short list) in the COS; an a priori definition of agreement required ≥70% of panellists to agree.

Next, small-group discussions and results were presented to the whole group. Where there was
| Domain                                                                 | Episodic migraine | Chronic migraine |
|-----------------------------------------------------------------------|-------------------|------------------|
| **Section 1: life impact: symptoms associated with headache/migraine** |                   |                  |
| Cognitive function: difficulty concentrating, ability to ‘think clearly’ or to remember things | (A) Yes A* | A*              |
| Increased sensitivities: to light, sound, smell and touch             | A*               | A*              |
| Pain associated with headache: experience an unpleasant physical sensation that aches or hurts | A** A* | A*          |
| Duration of pain: associated with a headache                          | A** A*           | A*          |
| Frequency of pain: associated with a headache                         | A** A*           | A*          |
| Severity/intensity of pain: associated with a headache               | A** A*           | A*          |
| Physical fatigue: experiencing physical fatigue, tiredness, lacking in energy and feeling physically exhausted | (A) Yes A* | A*          |
| Sleep quality: being able to have a restful sleep                     | (A) A*           |                  |
| Vomiting and/or feelings of nausea                                    | A* (A)           |                  |
| Anxiety: concerned, worried, fearful or anxious                       | (A) Yes (A) Yes |                  |
| Depressive mood: feeling sad, feeling down, feeling sorry for oneself or feeling depressed | (A) Yes (A) No |                  |
| **Section 2: life impact: functioning, activities and general well-being** |                   |                  |
| Activities of daily life                                              |                   |                  |
| Being able to carry out usual tasks or daily activities inside or outside the home (not related to paid employment) that support an independent lifestyle—such as tidying one’s home, walking short distances, managing finance, driving and using technology | (A) A* |                  |
| Needing to rest or lie down because of a headache                     | (A) A*           |                  |
| Emotional well-being                                                 |                   |                  |
| Feelings of isolation: feeling isolated and reduced social interactions | (B) Yes (A) Yes |                  |
| Self-worth: feeling like a burden to others; can include feeling valued or helpless, accepted or rejected; and feelings of self-esteem | (B) Yes (A) Yes |                  |
| Stress: feelings of distress, frustration or irritation               | A* (A) Yes       |                  |
| Work/education                                                       |                   |                  |
| Being able to carry out activities related to work (paid or unpaid)/study to an acceptable or usual standard | A* A** |                  |
| Needing to take time-off work (paid or unpaid)/study                 | A*               | A*              |
| Social life                                                          |                   |                  |
| Social life: relationships with colleagues or peers                   | A*               |                  |
| Family roles: being able to provide usual care and support for family and close friends | (A) Yes (A) Yes |                  |
| Participation in social or leisure activities: ability to participate in social or leisure activities | (A) Yes (A) Yes |                  |
| Overall health: an individual’s general health status; the ability to live a ‘normal’ life | A* A* |                  |
| Self-management: ability to effectively decrease/minimise/control the impact of migraine on oneself (eg, pharmacology, diet and lifestyle choices) | A* A* |                  |

Continued
agreement, no further discussion was required. Subsequent discussion focused on where further refinement was required. Finally, participants voted electronically to confirm domain placement in the COS (inner/middle/outer/out) and method of assessment. Proceedings were captured in the form of detailed written records and the outcomes of voting.

RESULTS
Stage 1: core domain set
Stage 1.1: developing a comprehensive domain list
A total of 57 (episodic) and 58 (chronic) domains were included in the questionnaire, grouped across four areas: symptoms (17), life impact (27 episodic/28 chronic), treatment effectiveness/financial impact (10) and complications (2). Piloting informed minor language modifications. Fifty-seven of the domains of interest were included for both EM and CM.

Table 1 Continued

| Domain                                                                 | Episodic migraine | Chronic migraine |
|-----------------------------------------------------------------------|-------------------|------------------|
| Unpredictability of a migraine: uncertainty of being symptom free or able to engage in activities | A*                | No (A)           |
| Trigger factors: ability to avoid/manage migraine trigger factors     | (B)               | Yes No           |
| Section 3: treatment effectiveness and financial impact               |                   |                  |
| Satisfaction with treatment                                          | A*                | A*               |
| Confidence in treatment                                              | A*                | A*               |
| Consistency of treatment effect                                       | A*                | A*               |
| Medication use: the type (potency) and dose (how much) medication taken when experiencing a migraine or headache | A*                | A*               |
| Medication use: the type (potency) and dose (how much) medication taken to prevent a migraine or headache | A*                | A*               |
| Financial impact: the economic cost associated with migraine treatment (to the individual (out of pocket expenses) and healthcare systems) | (A)               | A*               |
| Use of healthcare resources in response to migraine                  | (A)               | A*               |
| Section 4: complications (adverse events)                            |                   |                  |
| Treatment side effects: experiencing undesirable secondary effects from taking medications for migraine | A*                | A**              |
| Mortality (death)                                                    | (A)               | A**              |
| Included in round 2 due to importance scores (A** or A*)             | 18                | 24               |
| Included in round 2 due to qualitative feedback                      | 9                 | 7                |
| New outcomes added due to qualitative feedback                       | 0                 | 0                |
| Total number of outcomes for inclusion in round 2                    | 27                | 31               |

Each outcome was assigned to one of six categories reflecting levels of agreement: outcomes classified A** and A* would be included in round 2.
A*: if in both subpanels ≥70% rate an outcome is ≥7.
A**: if in both subpanels the median rating is 9.
(A): if in both subpanels the median outcome rating is ≥7.
(B): if the median rating for an outcome is ≥7 in only one subpanel.

Stage 1.2: international modified Delphi process

Round 1
Sub-panel 1 (patients): two organisations advertised the study (Migraine Association, Ireland, and National Migraine Centre, UK). Almost 80% (76/96) of patients who expressed an interest in taking part in the study completed the first questionnaire (42/53 CM (79%) and 34/43 EM (79%)). Most were female (CM: 40/53 (75%); EM: 29/43 (66%)) and aged between 36–45 years (CM: 41%) and 56–65 years (EM: 32%) (range: 18–>66 years). Most were from the UK (57%), followed by the USA (19%), Ireland (14%), Canada (2%) and the rest of Europe (Denmark (2%) and France (5%)).

Sub-panel 2 (professionals): from a total of 198 international healthcare professionals/researchers invited to participate, 64 agreed. Nearly half (31/64 (48%)) joined the panel to complete the EM questionnaire; slightly more (33/64 (52%)) completed the CM questionnaires.
Table 2 Delphi round 2. Results of domain prioritisation for episodic migraine (combined panels, n=27)†

| Rank* | Proposed ‘merged’ domain and definition | Top 10/27 prioritised domains | Top 50% of prioritised domains (rank 1–13/27 inclusive) | Lower 50% of prioritised domains (rank 14–27 inclusive) |
|-------|----------------------------------------|------------------------------|--------------------------------------------------------|-------------------------------------------------------|
| 1     | Pain | Experience of an unpleasant sensation that aches or hurts in the head; the frequency, severity and duration of this pain is important | Pain associated with migraine—experience of an unpleasant sensation that aches or hurts (1/27) | Frequency of pain associated with a migraine (2/27) |
|       |     |                                                                                                         | Severity or intensity of pain associated with a migraine (3/27) | Duration of pain associated with a migraine (4/27) |
| 2     | Usual activities | Being able to carry out usual activities (including paid or unpaid work, study, domestic chores, care or support for family or close friends) to an acceptable or usual standard | Being able to carry out activities related to work (paid or unpaid) or study to an acceptable or usual standard (5/27) | Family roles—able to provide usual care or support for family or close friends, including ability to commit activities (11/27) |
|       |     | Being able to participate in, or commit to, usual activities |                                                                                                           | Needing to take time off work (paid or unpaid) or study (13/27) |
|       |     |                                                                                                         |                                                                                                           | Participation in social or leisure activities—ability to participate in, or commit to, social or leisure activities (22/27) |
| 3     | Cognition | Difficulty concentrating, ability to ‘think clearly’, or to remember things | Cognitive function—difficulty concentrating, ability to think ‘clearly’ or to remember things (6/27) | |
| 4     | Adverse events | Treatment side effects—experiencing undesired secondary effects from taking medications for a migraine (7/27) | |
| 5     | Overall health | An individual’s general health status; the ability to ‘live a normal life’ (8/27) | |
| 6     | Self-management | Trigger factors—the ability to avoid/manage migraine trigger factors (9/27) | Unpredictability of a migraine—uncertainty of being symptom free or able to engage in activities (17/27) | |
| 7     | Associated symptoms | Increased sensitivities—to light, sound, smell or touch (10/27) | Vomiting and/or feelings of nausea (15/27)† prioritised in top 10 (10/27) by patients | Physical fatigue—experiencing physical fatigue, tiredness, lacking in energy and feeling physically exhausted (18/27)† prioritised in top 50% (11/27) by patients |

† prioritised in top 10 (10/27) by HCPs

Continued
Most were from the UK 14/33 (42%), with participants from the USA 5/33 (15%), Europe (Belgium 1/33 (3%), Germany 2/33 (6%), Italy 1/33 (3%), the Netherlands 1/33 (3%), Portugal 1/33 (3%), Serbia 1/33 (3%), Spain 2/33 (6%) and Turkey 1/33 (3%)), the Russian Federation 1/33 (3%), South Africa 1/33 (3%) and Thailand 1/33 (3%). Professionals included neurologists, nurse specialists, general practitioners, allied health professionals, researchers and measurement experts (online supplemental table 2).

In total, 75 (64%) and 65 (61%) panellists completed round 1 CM and EM questionnaires, respectively.

Most domains were rated as ‘important’, with few between panel discrepancies. Implementation of the a priori decision rule (online supplemental table 1) supported a 50% reduction in domains, with the prioritisation of 18/57 (episodic) and 24/58 (chronic) domains (table 1).

Qualitative feedback informed further consideration of 10 domains (9 episodic and 7 chronic) not achieving the proposed benchmark. No ‘new’ domains were proposed.

When prioritised according to the top 10 and top 50% of domains, several overriding ‘meaningful’ domains could be described (tables 2 and 3), six of which were common to both EM and CM: pain, usual activities, cognition, adverse events, overall health and associated symptoms. Respondents to the EM questionnaire also prioritised self-management, while medication use was prioritised by respondents to the CM.

Subpanel discrepancies for both EM and CM included patients’ prioritisation of overall health, physical fatigue, unpredictability and self-management. Patients with EM also prioritised emotional well-being. Although awarded fewer points, people with CM prioritised the importance of social role and emotional well-being. In contrast, healthcare professionals prioritised treatment satisfaction, treatment side effects and vomiting/nausea for EM, and mortality and stress for CM.

Round 3
Round 3 was completed by 23/23 (100%) and 21/29 (72%) health professionals, and 29/33 (88%) and 23/25 (92%) patients with CM and EM, respectively (totalling 52/56 (93%) for CM and 44/54 (81%) for EM. Discrepancies in six and three domains (top 10 or top 50% for one subpanel only) were considered for EM (treatment satisfaction, vomiting/feelings of nausea, medication taken during a migraine, satisfaction with treatment (14/27)† prioritised in top 10 (9/27) by HCPs
The type (potency) and dose (how much) of a medication taken when experiencing a migraine (18/27)† prioritised in top 50% (11/27) by HCPs
The type (potency) and dose (how much) of a medication taken to prevent a migraine (21/27)
Consistency in treatment (23/27)
Confidence in treatment (25/27)

Anxiety (19/27)
Depression (19/27)† prioritised in top 50% (13/27) by patients
Stress (24/27)
Self-worth (24/27)
Isolation (27/27)

*Top 7 grouped domains: informed by top 10 and top 50% of prioritised domains (13/27).
†6 domains prioritised differently between the two panels, considered further in round 3.
HCPs, healthcare professionals.

Table 2

| Rank* | Proposed ‘merged’ domain and definition | Top 10/27 prioritised domains | Top 50% of prioritised domains (rank 1–13/27 inclusive) | Lower 50% of prioritised domains (rank 14–27 inclusive) |
|-------|----------------------------------------|-----------------------------|--------------------------------------------------------|----------------------------------------------------------|
| 8     | Medication use                         |                             | Satisfaction with treatment (14/27)† prioritised in top 10 (9/27) by HCPs | The type (potency) and dose (how much) of a medication taken when experiencing a migraine (18/27)† prioritised in top 50% (11/27) by HCPs |
|       |                                        |                             | The type (potency) and dose (how much) of a medication taken to prevent a migraine (21/27) | Consistency in treatment (23/27) |
|       |                                        |                             | Confidence in treatment (25/27) | |
| 9     | Emotional well-being                   | Anxiety (19/27)† prioritised in top 50% (13/27) by patients | Depression (19/27)†, Stress (24/27), Self-worth (24/27), Isolation (27/27) |

*Top 7 grouped domains: informed by top 10 and top 50% of prioritised domains (13/27).
†6 domains prioritised differently between the two panels, considered further in round 3.
Table 3  Delphi round 2. Results of domain prioritisation for chronic migraine (combined panels n=31)†

| Rank* | Domain and definition | Top 10/31 prioritised domains | Top 50% of prioritised domains (rank 1–15/31 inclusive) | Lower 50% of prioritised domains (rank 16–31 inclusive) |
|-------|-----------------------|-------------------------------|----------------------------------------------------------|----------------------------------------------------------|
| 1     | Pain                  | Severity or intensity of pain associated with a migraine (1/31) | Pain associated with a migraine—experience of an unpleasant sensation that aches or hurts (2/31) | Frequency of pain associated with a migraine (3/31) |
|       |                       |                               | Duration of pain associated with a migraine (4/31)       |                                                          |
|       |                       |                               |                                                          |                                                          |
| 2     | Usual activities      | Being able to carry out usual tasks or daily activities inside or outside the home (not related to paid employment) that support an independent lifestyle—such as tidying one’s home, walking short distances, managing finance, driving, usual technology (instrumental activities of daily life) (5/31) | Being able to carry out usual tasks or daily activities inside or outside the home (not related to paid employment) that support an independent lifestyle—such as tidying one’s home, walking short distances, managing finance, driving, usual technology (instrumental activities of daily life) (5/31) | Needing to take time off work (paid or unpaid) or study (11/31) |
|       |                       |                               |                                                          |                                                          |
| 3     | Cognition             | Cognitive function—difficulty concentrating, ability to ‘think clearly’ or to remember things (7/27) |                                                          |                                                          |
|       |                       |                               |                                                          |                                                          |
| 4     | Adverse events        | Treatment side effects—experiencing undesired secondary effects from taking medications for migraine (8/31) |                                                          | Mortality (death) (26/31)† prioritised in top 50% (15/31) by HCPs |
|       |                       |                               |                                                          |                                                          |
| 5     | Associated symptoms   | Increased sensitivities—to light, sound, smell or touch (9/31) | Physical fatigue—experiencing physical fatigue, tiredness, lacking in energy and feeling physically exhausted (10/31) | Sleep quality—being able to have a restful sleep (14/31) |
|       |                       |                               |                                                          | Needing to rest or lie down because of a headache (15/31) |
|       |                       |                               |                                                          |                                                          |
| 6     | Medication use        | Satisfaction with treatment (12/31) |                                                          | The type (potency) and dose (how much) of a medication taken to prevent a migraine (21/31) |
|       |                       |                               |                                                          | Consistency in treatment effect (23/31) |
|       |                       |                               |                                                          | The type (potency) and dose (how much) of a medication taken during a migraine (24/31) |
|       |                       |                               |                                                          | Confidence in treatment (28/31) |
| 7     | Overall health        | An individual’s general health status; the ability to ‘live a normal life’ (13/31) |                                                          |                                                          |

Continued
unpredictability, physical fatigue and depressive mood) and CM (stress, mortality and unpredictability), respectively (online supplemental table 3).

The seven domains for EM were retained (>76% across sub-panels; >84% combined) (table 4) and a new domain ‘treatment satisfaction’ proposed (>70% healthcare professionals; 68% combined) (online supplemental table 3). Voting on subpanel discrepancies further supported the inclusion of vomiting/feelings of nausea, physical fatigue and depressive mood within the developing CDS for EM (online supplemental table 3). Qualitative feedback in the questionnaire supported a more positive rephrasing of the concept of self-management.

Six of the seven domains for CM were retained (>73% across sub-panels; >80% combined) (table 4). ‘Medication use’ was rejected (<70%), and a redefining as ‘treatment satisfaction’ proposed. Qualitative feedback further supported the inclusion of ‘visual disturbances’ from ‘associated symptoms’, and the movement of ‘sleep quality’ to ‘usual activities’.

For both EM and CM, qualitative feedback highlighted the importance of communication difficulties within cognitive function; further consideration of vomiting/nausea, physical fatigue and depressive mood as additional ‘associated symptoms’; and unpredictability and ability to uphold usual commitments within ‘usual activities’. Further clarification of the concept of ‘overall health’—for example, general or migraine-specific health—was proposed and adoption of a standardised definition of ‘adverse events’ (Common Terminology Criteria for Adverse Events).28

The process defined seven core domains common to EM and CM (table 4). Additionally, EM included ‘self-management’.

### Stage 2: core measurement set

#### International expert panel face-to-face meeting

The 1-day meeting took place at Warwick University in December 2018. Seven patients (three with EM and four with CM) and seven healthcare professionals/researchers (two doctors, two nurses, one physiotherapist and two measurement experts) participated from two countries (UK and Portugal). Ten core group members, including two patient research partners (GP and BB), attended.

#### Pain

Pain was redefined as migraine-specific pain and endorsed as an inner core domain for EM and CM (>70%) (table 5; figure 2). Based on review of existing measures and group discussion, voting supported recommendation of the 11-point NRS for assessing pain intensity29 and number of headache/migraine
Table 4  Delphi round 3. Results of voting for domains for EM and CM

| Proposed core domains for EM and CM (For voting in round 3) | EM Voting | CM Voting |
|------------------------------------------------------------|-----------|-----------|
| Prioritised domains (informed by round 2)                  | Q         | Patient (n=23) | Combined (n=44) | Patient (n=29) | HCPs (n=23) | Combined (n=52) |
| Pain                                                      | (a)       | 100.0%       | 100.0%       | 100.0%       | 96.6%       | 86.9%       | 92.3% |
|                                                           | (b)       | 82.6%       | 100.0%       | 90.9%       | 89.7%       | 95.7%       | 92.3% |
| ► Pain associated with a migraine—an unpleasant sensation that aches or hurts |           |             |             |             |             |             |       |
| ► Frequency of pain associated with a migraine             |           |             |             |             |             |             |       |
| ► Severity or intensity of pain associated with a migraine |           |             |             |             |             |             |       |
| ► Duration of pain associated with a migraine              |           |             |             |             |             |             |       |
| Overall health                                            | (a)       | 100.0%       | 90.5%       | 95.5%       | 96.6%       | 87.0%       | 92.3% |
|                                                           | (b)       | 87.0%       | 81.0%       | 84.1%       | 89.7%       | 78.3%       | 84.6% |
| ► An individual’s health status; the ability to live a ‘normal’ life |           |             |             |             |             |             |       |
| Qualitative feedback challenged the concept of ‘normal life’ and the lack of clarity with regards to either migraine-specific or general quality of life. This would be further explored during the consensus meeting. |           |             |             |             |             |             |       |
| Usual activities                                          | (a)       | 95.7%       | 81.0%       | 88.6%       | 100.0%      | 95.7%       | 98.1% |
|                                                           | (b)       | 95.7%       | 76.2%       | 86.4%       | 89.7%       | 95.7%       | 92.3% |
| ► Being able to carry out activities related to work (paid or unpaid) or study to an acceptable or usual standard |           |             |             |             |             |             |       |
| ► Family roles—able to provide usual care or support for family or close friends, including to commit to activities (EM only) |           |             |             |             |             |             |       |
| ► Need to take time off work (paid or unpaid) or study     |           |             |             |             |             |             |       |
| ► Being able to carry out usual tasks or daily activities inside or outside the home (not related to employment) that support an independent lifestyle—such as tidying one’s home, walking short distances, managing finances, driving and using technology (CM only) |           |             |             |             |             |             |       |
| Cognitive function                                        | (a)       | 95.7%       | 100.0%      | 97.7%       | 96.6%       | 95.7%       | 96.1% |
|                                                           | (b)       | 91.3%       | 90.5%       | 90.9%       | 93.1%       | 95.7%       | 94.2% |
| ► Cognitive function—difficulty concentrating, ability to think ‘clearly’ or to remember things |           |             |             |             |             |             |       |
| Qualitative feedback supported the addition of:           |           |             |             |             |             |             |       |
| ► Difficulty with communication (word finding, slow or slurred speech) |           |             |             |             |             |             |       |

Continued
### Table 4  Continued

| Proposed core domains for EM and CM (For voting in round 3) | EM Voting | CM Voting |
|-----------------------------------------------------------|-----------|-----------|
| **Averse effects**                                        |           |           |
| Treatment side effects — experiencing undesired secondary effects from taking medications for migraine | (a) 100.0% 100.0% 100.0% | (a) 89.7% 95.7% 92.3% |
| Experiencing undesired secondary effects from taking medications for a migraine | (b) 87.0% 90.5% 88.6% | (b) 93.1% 82.6% 88.5% |
| Qualitative feedback supported adoption of the CTCAE standardised definition of adverse events: |           |           |
| ‘any unfavourable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure.’ (CTCAE reference) |           |           |
| **Associated symptoms**                                   |           |           |
| Increased sensitivities — to light, sound, smell or touch | (a) 87.0% 100.0% 93.2% | (a) 96.6% 73.9% 86.5% |
| Increased sensitivities — to light (photophobia), sound (phonophobia), smell, touch or movement | (b) 87.0% 90.5% 88.6% | (b) 93.1% 73.9% 84.6% |
| Physical fatigue — experiencing physical fatigue, tiredness, lacking in energy and feeling physically exhausted (CM only) |           |           |
| Physical fatigue — experiencing physical fatigue, tiredness, lacking in energy and feeling physically exhausted (CM only) |           |           |
| Sleep quality — being able to have a restful sleep (CM only) |           |           |
| Needing to rest or lie down because of a headache (CM only) |           |           |
| Qualitative feedback highlighted concern over the omission of the following components from associated symptoms: |           |           |
| Visual disturbances |           |           |
| Depressive mood |           |           |
| Vomiting/feelings of nausea |           |           |
| All to be explored in consensus meeting (for both EM and CM) |           |           |
| **Satisfaction with treatment**                           |           |           |
| Medication use voting: proposed domain rejected (values <70%) | (a) N/A N/A N/A | (a) 79.3% 69.6% 75.0% |
| Qualitative feedback highlighted the importance of a domain that was not just focused on medication use. |           |           |
| Note: voting on subgroup discrepancies supported the inclusion of ‘treatment satisfaction’ as a domain within the EM domain set. |           |           |
| Core group recommendation that ‘treatment satisfaction’ is explored in consensus meeting for both EM and CM |           |           |

Continued
days per month for pain frequency. Due to the complexities around the concepts of headache and migraine, it was recommended that the specific terminologies should be defined by individual studies.

**Overall health**

Overall Health was redefined as ‘migraine-specific quality of life’ (MSQoL), endorsed as an inner core domain for both EM and CM (table 5; figure 2). Presented with evidence for generic and migraine quality of life measures, participants preferred the Migraine Functional Impact Questionnaire (MFIQ). The four domain scores of the MFIQ address several key concepts highlighted throughout the COSMIG process—including usual activities, physical, cognitive, social and emotional functions. It also provides a global item score for usual activities.

**Pain duration and associated symptoms**

Pain duration and associated symptoms were both judged as important but not feasible for inclusion in all trials/research studies and placed in the middle circle (table 5; figure 2).

**Self-management and treatment satisfaction**

Self-management and treatment satisfaction were both considered important for both EM and CM, but lack of conceptualisation and assessment supported their placement on the research agenda (outer circle) (table 5; figure 2).

**Cognitive function and usual activities**

Cognitive function and usual activities were both rejected as independent core domains but proposed as important components of MSQoL (table 5).

**Adverse events**

Adverse event was rejected as a core domain, with the proposition that such reporting should be part of good clinical practice guidance (table 5; figure 2).

The result was a two-domain COSMIG (table 5; figure 2):

1. Migraine-specific pain: intensity assessed with the 11-point NRS and frequency as the number of headache/migraine days over a specified period.
2. MSQoL: assessed with the MFIQ.

**DISCUSSION**

The COSMIG process has identified two core domains—pain and MSQoL—that are recommended as part of a priori designated outcomes in future preventive intervention clinical trials for both EM and CM. Pain assessment should include both intensity measured with an 11-point NRS, and frequency assessed as the number of headache/migraine days per 28 days. SQoL should be assessed with the MFIQ. Complex concepts around headache and migraine meant that participants in the consensus meeting were not able to make recommendations for the phrasing...
Table 5  Consensus meeting. Results from small and large group discussions and voting

| Domain          | Small group                                      | Large group                                      | Final decision*                                                                 |
|-----------------|--------------------------------------------------|--------------------------------------------------|---------------------------------------------------------------------------------|
| **Pain**        | Domain Voting supported inclusion of pain for EM and CM (>70%) | Domain Inner core: migraine-specific pain (no further voting required) | Domain – both EM and CM Inner core: migraine-specific pain Components: intensity and frequency Measurement Pain intensity: 11-point NRS (anchors ‘no pain’ and ‘pain as bad as you can imagine’) Pain frequency: the number of headache/migraine days (>70%) Pain duration: no consensus. Proposed that daily capture (using paper or electronic diary) or retrospective capture using a questionnaire may not be feasible for all trials Voting: middle circle (89%) |
|                 | Three aspects of pain included:                 | Measurement                                      |                                                                                 |
|                 | ► Intensity (11/11)                              | Pain intensity: 11-point NRS (80%)               |                                                                                 |
|                 | ► Frequency (10/11)                              | Pain frequency: the number of headache/migraine days (>70%) |                                                                                 |
|                 | ► Duration (8/11)                                | Pain duration: no consensus. Proposed             |                                                                                 |
|                 | Proposed domain refinement to 'migraine-specific pain' | that daily capture (using paper or electronic diary) or retrospective capture using a questionnaire may not be feasible for all trials |                                                                                 |
|                 | Measurement                                      | Voting for all trials                            |                                                                                 |
|                 | Voting for individual options did not exceed 70%|                                                                                   |                                                                                 |
|                 | Preferred assessments:                          |                                                                                   |                                                                                 |
|                 | Intensity: 11-point NRS (55%)                    |                                                                                   |                                                                                 |
|                 | Frequency: number of headache/migraine days (64%)|                                                                                   |                                                                                 |
|                 | Duration: cumulative hours per 28 days of moderate/severe pain (55%) |                                                                                   |                                                                                 |
| **Overall Health** | Domain Voting supported redefining domain as migraine-specific quality of IMSQoLife (73%) | Domain Inner core: MSQoL (no further voting required) | Domain – both EM and CM Inner core: MSQoL Measurement |
| **Adverse events** | Domain Voting supported the rejection of adverse events from the core domain set (82%) | Domain Recommendations were supported. Should be captured as part of good clinical practice guidance | Not included in the COS for EM or CM |
| **Self-management** | Domain No consensus on the inclusion (46%)/ exclusion (54%) of self-management. Participants considered it to be important to both EM and CM, but requiring greater conceptualisation before it can be accurately measured | Domain Group confirmed the importance of self-management for both EM and CM, but agreed that the lack of conceptualisation and method of assessment prevented inclusion in the COS Voting: research agenda (73%) | Domain and measurement—both EM and CM Outer circle: research agenda: important but requiring further study |
| **Cognitive function** | Domain Voting supported the rejection of cognitive function as a separate core domain (70%) but participants supported cognitive function as an important concept | Domain Recommendations supported. The importance of cognitive function was supported and the potential for it to be captured with MSQoL proposed | Not included as a separate core domain for EM or CM. Cognitive function is included within the new domain MSQoL and will be assessed by the MFIQ |
| **Associated symptoms** | Domain No consensus on the inclusion (50%)/exclusion (50%) of associated symptoms. Participants discussed the importance of a wide range of associated symptoms— but capture of all would not be feasible in all trials (and hence not core) | Domain Participants recognised pain as an important ‘associated symptom’ and the inclusion of several additional associated symptoms within the new domain ‘MQoL’ (captured by the MFIQ). Capturing a larger number of associated symptoms, or specific additional symptoms—such as fatigue—should be study specific and not core | Domain and measurement—both EM and CM Middle circle: important but not feasible to include in all trials/research studies |
| **Usual activities** | Domain Voting supported the inclusion as a component of a new domain ‘MQoL’ (100%) | Domain Recommendations were supported Measurement | Not included as a separate core domain for EM or CM. Usual activities is included within the new domain ‘MSQoL’ and will be assessed by the MFIQ |
|                 | Measurement                                      | N/A                                |                                                                                 |
|                 | Usual activities, as a component of MQoL to be assessed with the MFIQ (80%) |                                                                                   |                                                                                 |
of questions on pain severity (eg, worst, average or typical) or the definition of a migraine/headache day. Thus, the specific terminologies should be defined, and reported, by the needs of individual studies. Likewise, the specific timing of assessments should be driven by the requirements of the study.

Participants in the consensus meeting preferred the MFIQ over other measures of migraine-related quality of life such as the MSQoL Questionnaire V.2.1 and the 6-item Headache Impact Test (HIT-6) because participants, in particular, patient participants, felt its domains best reflected the impact migraine has on people’s lives. This matches the aims of the original developers who specifically sought to address gaps in existing patient-reported outcomes.31 A licence is needed to use the MFIQ available from Legal@evidera.com. The owners advise us that it will be available free of charge for non-commercial research (email, Evidera, 15 May 2020, personal communication).

Pain duration and associated symptoms are important but are not considered core. How to assess self-management and treatment satisfaction requires further research before recommendations can be made.

Our recommendation to include a reduction in the severity (intensity) and frequency in migraine pain is further supported by a recent modified Delphi study conducted in the USA, which sought to identify outcomes for value-based contracting for migraine medications.32 However, a Delphi study of experts (N=12), published after our work was completed, focused on establishing the most useful outcome measures, specifically for non-pharmacological interventions for migraine, and identified the Migraine Disability Assessment followed by the HIT-6 as preferred outcomes.33 Our empirical work does not support this prioritisation of outcome measures.2 34

The COSMIG recommendations contrast with previous guidance for trials of prophylaxis in CM that recommend a single primary outcome derived from headache/migraine days. Patient-reported headache-related quality of life appears last in order of the secondary outcomes1 and guidelines for trials of prophylaxis in EM do not include quality of life as an outcome.13 Informed by current good practice guidance in COS development,9 14 this study included international participation from patient and professional panellists in an online Delphi study and a subsequent face-to-face meeting. All data pertaining to the Delphi study were analysed both separately and combined to ensure that the views of subpanels were clearly reported. This approach highlighted the value placed on patient-reported outcomes such as pain and quality of life by patients and health professionals. However, discrepancies pertaining to, for example, the importance of fatigue, unpredictability, emotional impact and cognitive function were described. Such discrepancies have been reported in other long-term musculoskeletal conditions35 and more recently in a survey of health professionals and patients with COVID-19.36 Evidence of such discrepancies is a key driver for the suggestion that patients’ views are given at least equal weight to those of professionals in the process of COS development.9 Incorporating outcomes that have resonance to all stakeholders can enhance trial relevance, providing valued information to inform decision-making in clinical practice and health policy settings.

Table 5

| Domain                        | Small group                                                                 | Large group                                                                 | Final decision* |
|-------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|-----------------|
| Treatment satisfaction        | Domain considered important—but no consensus on the inclusion (64%)/exclusion (36%) of treatment satisfaction due to need for greater clarity | Domain confirmed the importance of treatment satisfaction for both EM and CM, but agreed that the lack of conceptualisation and method of assessment prevented inclusion in the COS | Domain and measurement—both EM and CM.35 Outer circle: research agenda: important but requiring further study |

*Core ‘inner’ circle: domain is unambiguous with an acceptable method of assessment. Middle circle: domain is important, but not feasible for all preventative trials and research studies. Outer circle: domain is important, but requires further study (research agenda)—for example, lacks conceptual clarity or method of assessment.

CM, chronic migraine; COS, core outcome set; EM, episodic migraine; MFIQ, Migraine Functional Impact Questionnaire; MSQoL, migraine-specific quality of life; NRS, Numerical Rating Scale.

Figure 2 COSMIG: core outcome set for episodic and chronic migraine.
While individuals from 14 countries were included in the Delphi study, participants from just two countries (England and Portugal) contributed to the face-to-face meeting. However, both the Delphi process and consensus meeting sought input from credible ‘experts’.\(^1\)\(^7\)\(^9\) For patients, expert is defined by experience of living with CM or EM, and for health professionals by their relative expertise in migraine-related research. The wide international involvement throughout the Delphi study improved international reach and helped ensure a wider relevance of the recommendations. We note that Delphi results are obtained from inviting experts to join a panel; as this eschews sampling, no inference should be made to any larger definable population. Active pre-engagement with potential participants in the Delphi study enabled targeted follow-up of non-responders in round 1.\(^3\)\(^7\)\(^9\) We note that the participation rate of invited panellists is higher than reported in some other Delphi studies, where response rates between 30% and 40% have been reported.\(^2\)\(^1\)\(^)\(^)\(^)\(^)\(^.\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\(^)\[^{
studies receiving additional support from Stryker; has accepted honoraria for teaching/lecturing from CARTA; and was an editor of the NIHR journal series and a member of the NIHR Journal Editors Group, for which he received a fee. MM serves on the advisory board for Abbott, Allergan, Eli Lilly, Medtronic, Novartis and TEVA; has received payment for the development of educational presentations from Allergan, electroCore, Eli Lilly, Medtronic, Novartis and TEVA; and has received research grants from Abbott, electroCore and Medtronic. SP is a director of Health Psychology Services, which, in part, provides psychological treatments for those with chronic pain.

Patient consent for publication Not required.

Ethics approval Ethical approval was gained from Warwick Medical School’s Biomedical and Scientific Research Ethics Committee (approval number: REGO 2017–1921).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. De-identified data will be shared through the university accessible databases or repositories at Warwick University. Please contact KH if additional information is required: k.l.haywood@warwick.ac.uk.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, a link to the licence is given, and any translated material is included. This article meets the requirements of the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, a link to the licence is given, and any translated material is included.

REFERENCES

1. Tassorelli C, Diener H-C, Dodick DW, et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia 2018;38:815–32.

2. Haywood KL, Mars TS, Potter R, et al. Assessing the impact of headaches and the outcomes of treatment: a systematic review of patient-reported outcome measures (PROMs). Cephalalgia 2018;38:1373–86.

3. Probyn K, Bowers H, Caldwell F, et al. Prognostic factors for chronic headache: a systematic review. Neurology 2017;89:291–301.

4. Clarke M. Standardising outcomes for clinical trials and systematic reviews. Trials 2007;8:39.

5. Kirkham JJ, Gargan E, Clarke M, et al. Can a core outcome set improve the quality of systematic reviews?—a survey of the Coordinating Editors of Cochrane Review Groups. Trials 2013:14:21.

6. Jackson JL, Cogbill E, Santana-Davila R, et al. A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. Pain 2013;155:200–9.

7. Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007;47:170–80.

8. Kirkham JJ, Dwan KM, Altman DG, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340:c365.

9. Williamson PR, Altman DG, Bagley H, et al. The comet Handbook: version 1.0. Trials 2017;18:280.

10. Williamson PR, Altman DG, Blazeby JM, et al. Developing core outcome sets for clinical trials: issues to consider. Trials 2012;13:132.

11. Gorst SL, Gargan E, Clarke M, et al. Choosing important health outcomes for comparative effectiveness research: an updated review and user survey. PLoS One 2016;11:e0146444.

12. Tunis SR, Clarke M, Gorst SL, et al. Improving the relevance and consistency of outcomes in comparative effectiveness research. J Comp Eff Res 2016;5:193–205.

13. Thlift-Hansen P, Pascual J, Ramadan N, et al. Guidelines for controlled trials of efficacy in migraine: third edition. A guide for investigators. Cephalalgia 2012;32:6–38.

14. Boers M, Kirwan JR, Wells G, et al. Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. J Clin Epidemiol 2014;67:745–53.

15. Ward F, Popay J, Porroche-Escudero A, et al. Mainstreaming public involvement in a complex research collaboration: a theory-informed evaluation. Health Expect 2020;23:910–8.

16. Nichols VP, Ellard DR, Griffiths FE, et al. The lived experience of chronic headache: a systematic review and synthesis of the qualitative literature. BMJ Open 2017;7:e019593.

17. Murphy MK, Black NA, Lamping DL, et al. Consensus development methods, and their use in clinical Guideline development. Health Technol Assess 1998;2:i–1–88.

18. Henshaw O, Dalkey N. An experimental application of the Delphi method to the use of books. The Rand Corporation Memorandum RM 727/1 – Abridged July 2961, 1962.

19. Fink A, Kosecoff J, Chassin M, et al. Consensus methods: characteristics and guidelines for use. Am J Public Health 1984;74:979–83.

20. Orbai A-M, de Wit M, Mease P, et al. International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Ann Rheum Dis 2017;76:673–80.

21. Prinsen CA, Vohra S, Rose MR, et al. How to select outcome measurement instruments for outcomes included in a “Core Outcome Set” – a practical guideline. Trials 2016;17:449.

22. International Headache Society. ICHD / guidelines, 2020. Available: https://www.ihns-headache.org/ichd-guidelines

23. The National Institute of Neurological Disorders and Stroke (NINDS). Common Data Standards - Headache. Available: https://www.commondataelements.ninds.nih.gov/headache [Accessed 01 Apr 2020]

24. Dworin HK, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMPACT recommendations. Pain 2005;113:9–19.

25. Turk DC, Dworin RH, Allen RR, et al. Core outcome domains for chronic pain clinical trials: IMPACT recommendations. Pain 2003;106:337–45.

26. IMPACT. Initiative on methods, measurement, and pain assessment in clinical trials. Available: http://www.impact.org [Accessed Apr 2020]

27. Tugwell P, Boers M, Brooks P, et al. OMERACT: an international initiative to improve outcome measurement in rheumatology. Trials 2007;3:8.

28. Institute NC. Common terminology criteria for adverse events (CTCAE). Available: https://ctep.cancer.gov/protocoldevelopment/ electronic_applications/ctc.htm [Accessed Apr 2020]

29. Hjemstad MJ, Fayers PM, Haugen DF, et al. Studies comparing numerical rating scales, verbal rating scales, and visual analogue scales for assessment of pain intensity in adults: a systematic literature review using the Morbidity and Mortality Reporting System. J Pain Symptom Manage 2011;41:1072–83.

30. Hareendran A, Skalicky A, Mannix S, et al. Development of a New Tool for Evaluating the Benefit of Preventive Treatments for Migraine on Functional Outcomes - The Migraine Functional Impact Questionnaire (MFIQ). Headache 2018;58:1612–28.

31. Kawata AK, Hareendran A, Shatller S, et al. Evaluating the psychometric properties of the migraine functional impact questionnaire (MFIQ). Headache 2019;59:1253–69.

32. Swart ECS, Good CB, Henderson R, et al. Identifying outcome measures for migraine value-based contracting using the Delphi method. Headache 2020;60:2139–51.

33. Luedtke K, Basener A, Bedei S, et al. Outcome measures for assessing the effectiveness of non-pharmacological interventions in frequent episodic or chronic migraine: a Delphi study. BMJ Open 2020;10:e029855.

34. Haywood KL, Achana F, Nichols V, et al. Measuring health-related quality of life in chronic headache: a comparative evaluation of the chronice headache quality of life questionnaire and headache impact test (HIT-6). Cephalalgia 2021;41:1100–23.

35. Czarzewska S, Haywood KL, Brett J, et al. Patient and public involvement in patient-reported outcome measures: evolution not revolution. Patient 2012;5:79–87.

36. Evangelidis N, Tong A, Howell M, et al. International survey to establish Prioritized outcomes for trials in people with coronavirus disease 2019 (COVID-19). Trials 2021;22:268.

37. Gargan E, Gorst SL, Williamson PR. Choosing important health outcomes for comparative effectiveness research: 5th annual update to a systematic review of core outcome sets for research. PLoS One 2019;14:e0225980.
APPENDIX

Appendix Table 1. Bespoke grading system to illustrate where consensus was achieved in the Delphi Round 1 for reviewed domains.

| Grade | Level of agreement between panel | Decision rule |
|-------|----------------------------------|---------------|
| A **  | If in both panels the median rating is 9 | Include domain in Round 2 |
| A*    | If in both panels ≥70% rate a domain ≥7 | Include domain in Round 2 |
| A     | If in both panels the median domain rating is ≥7 | Include domain in Round 2 if either panel achieves a median score of 9 or qualitative evidence supports further consideration |
| B     | If the median rating for a domain is ≥7 in only one panel | Include domain in Round 2 if either panel achieves a median score of 9 or qualitative evidence supports further consideration |
| C     | If the median rating for the two panels combined is ≥4 and ≤6 and the median rating for no single panel is ≤7 | No progression to Round 2 (unless qualitative evidence supports further consideration) |
| D     | If the median rating for the two panels combined is ≥1 and ≤3 and the median rating for no single panel is ≤7 | No progression to Round 2 (unless qualitative evidence supports further consideration) |

Footnote: ‘both panels’ refers to – patient panel and professionals panel
Appendix Table 2. Background of professional participants (expert panel) in the Delphi process (Round 1).

| Professional Background                  | Chronic round | Episodic round |
|-----------------------------------------|---------------|----------------|
| Clinician                               | 6             | 5              |
| Neurologist                             | 13            | 12             |
| Neurologist specialist interest headache| 10            | 11             |
| GP specialist interest headache         | 1             | 0              |
| Nurse specialist                        | 4             | 3              |
| Chiro/osteopath/                        | 2             | 1              |
| Health Economist                        | 2             | 1              |
| Clinical Academic                      | 8             | 9              |
| Other health professional academic      | 2             | 0              |
| Clinical Trialist                       | 9             | 8              |
| Systematic reviewer                     | 6             | 5              |
| Measurement expert                      | 7             | 8              |

Footnote: participants could identify as having more than one background.
Appendix Table 3. Delphi Round 3: results of voting on sub-panel discrepancies.

| Discrepancies [outcomes rated in top 50% by one sub-panel] | Proposed Domain and definition | Q | EPISODIC MIGRAINE | CHRONIC MIGRAINE |
|-----------------------------------------------------------|--------------------------------|---|------------------|-----------------|
| Ranked highly by healthcare professionals (HCPs)          |                                |   | Patient (n=23)   | HCPs (n=21)     | Combined (n=44) |
| • HCP 9/27; Patients 20/27 (EM)                           | Satisfaction with Treatment    | a. | 65.2% | 71.4% | 68.2%         | -               | -               |
| • HCP 8/27; Patients 25/27 (EM)                           | Vomiting and/ feelings of nausea | a. | 60.9% | 71.4% | 65.9%         | -               | -               |
| • HCP 12/27; Patients 18/27 (EM)                          | Type (potency) and dose (how much) of a medication when experiencing a migraine   | a. | -     | -     | -             | -               | -               |
| • HCP 10/31; Patients 20/31 (CM)                          | Stress – feelings of distress, frustration or irritation                       | a. | -     | -     | -             | 58.6%           | 47.8%           | 53.9% |
| • HCP 15/31; Patients 29/31 (CM)                          | Mortality (death)                                                           | a. | -     | -     | -             | 20.7%           | 17.4%           | 19.2% |

Ranked highly by patients

| • Patients 10/27; HCPs 21/27 (EM)                           | Unpredictability of a migraine – uncertainty of being symptom-free or able to engage in activities | a. | 82.6% | 61.9% | 72.7% | 96.6% | 69.6% | 84.6% |
| • Patients 14/31; HCPs 31/31 (CM)                          |                                                                                                  | a. | -     | -     | -     | -     | -     | -     |
| • Patients 11/27; HCPs 23/27 (EM)                          | Physical fatigue – experiencing physical fatigue, tiredness, lacking in energy, feeling physically exhausted | a. | 69.6% | 52.4% | 61.4% | -     | -     | -     |
| • Patients 10/27; HCPs 21/27 (EM)                          | Depressive mood – feeling sad, feeling down, feeling sorry for oneself, or feeling depressed       | a. | 69.6% | 42.9% | 56.8% | -     | -     | -     |

Footnote: Panellists were asked to indicate [Yes/No]: a. Should the following outcomes be included in a core set for studies of EM / CM (respectively)?